The issues and challenges in the prevention of persisting paralytic disease caused by polioviruses are different in the temperate climate countries with limited seasonal dissemination of polioviruses and in the subtropical and tropical countries with extensive year-round dissemination of polioviruses.
ISSUES AND CHALLENGES IN TEMPERATE CLIMATE COUNTRIES Countries Using Exclusively Oral Polio Vaccine (OPV) OPV has been used exclusively in temperate climate countries with a combined total population of almost 2,000 million people, including China, the USSR, the U.S.A., Japan, and many smaller countries in Europe, the Americas, and Oceania. The vaccination programs in these countries have varied considerably in the extent of vaccine coverage in initial national or regional mass campaigns for rapidly break- ing the chain of transmission of "wild" polioviruses as well as in subsequent vaccination of the oncoming generations of children; the continuous importation of "wild" polioviruses from adjacent regions or countries has also varied. Accordingly, it is not surprising that the extent to which paralytic poliomyelitis caused by polioviruses has been controlled in these countries has also varied from complete since 1960 (e.g., Czechoslovakia, East Germany) and almost complete in recent years (e.g., U.S.A., Japan, most of the USSR, most European countries, Australia, New Zealand, etc.) to extensive reduction in much of China.
In the U.S.A., the average estimated number of nonpersisting and persisting cases of paralytic poliomyelitis was 135 per million total population per year during the pre-vaccine period of [1951] [1952] [1953] [1954] [1955] It is noteworthy that this extraordinary elimination of paralytic poliomyelitis from the U.S.A. has been achieved despite (a) the large number of economically deprived one-to four-year-old children who have had no vaccine at all and the still larger number who had less than three doses [1] and (b) the continuous annual importation of "wild" polioviruses by thousands of Mexican families with small children.
If currently available more potent IPV would replace OPV in the U.S.A. as some are proposing [5] , the benefits derived from the current break in the chain of transmission of imported "wild" polioviruses and from the contact immunization of unvaccinated children [1] would disappear in due time, and the unvaccinated and those who lost their IPV-acquired immunity would again face the danger of paralytic disease caused by polioviruses.
Countries Using Exclusively IPV There is no question that more potent IPV, especially as used in multiple doses, in almost 100 percent of children in Sweden [6] , Finland [7] , and Holland [8] The control of paralytic poliomyelitis in Sweden is unquestionably due to the extensive vaccination of nearly 100 percent of the susceptible age groups with many doses of potent IPV [6] . Although the antibody status of preschool children in Sweden is much better than in Finland, the remarkable disappearance of detectable polioviruses may have the same explanation as in Finland, and cannot be attributed to the IPV-induced antibodies [1] .
In Holland, where nearly 100 percent of children (excepting certain religious groups) have for many years received many doses of more potent IPV [8] , the average annual incidence of about 11 paralytic cases per 100 million during the tenyear period of 1966-1975 is about three times more than was reported in the U.S.A. during the six-year period of 1973-1978 [1] . Recent reports by Bijkerk et al. [10] and by Kapsenberg et al. [11] In 1979, I analyzed the problem of elimination of paralytic poliomyelitis caused by polioviruses from econmically underdeveloped countries with inadequate health services and concluded that the problem was administrative and not immunological or epidemiological [14] . It was evident that the problem was not with the immunogenicity of OPV in these countries, as was assumed by the investigators who were selected to participate in the 1980 International Symposium on Reassessment of Inactivated Poliomyelitis Vaccine in Bilthoven, Holland [15] , but rather that the procedures of using OPV that were so highly effective in the temperate climate countries had to be modified in parts of the world where paralytic polioviruses are propagating throughout the year in a very large proportion of the infant population, even as early as the first month of life. It became evident to me almost 20 years ago that initial mass vaccination programs with OPV followed by routine vaccination concurrently with other vaccines routinely administered as part of regular health care during the first year of life which brought about such dramatically rapid elimination of the disease in many large and small temperate climate countries, had only a temporary impact in tropical countries, largely because a single mass campaign reaching even 90 percent or more of susceptible children only temporarily suppresses the circulation of "wild" polioviruses and also because subsequent routine vaccination programs at best reached only 20-40 percent of the total infant population. Under such conditions, even a hypothetical vaccine that would provide lifelong immunity in a single dose to 100 percent of children receiving it early in life could at best only reduce the incidence of the disease.
Twenty years ago, Cuba was the first country to introduce the procedure of national, annual mass vaccination campaigns with OPV on two Sundays of the year of all children under five years of age, regardless of how many doses they may have had before, with a rapid and lasting elimination of the disease [16] . In 1968, Dorothy Horstmann and I, as consultants to the Pan American Health Organization, recommended a similar program for other Latin American countries, but despite my repeated recommendations [3, 14] Brazil and Mexico have only recently adopted this procedure. The particular point in such annual national mass vaccinations with OPV is not only that the special organization of large numbers of nonprofessional personnel makes it possible to reach an extraordinarily high proportion of all children even in remote areas of large countries, but that most of the vaccination is carried out in one or two days which rapidly establishes a dominant circulation of the attenuated vaccine strains in the community [17] . When vaccination of children is spread out over a long period of time, as each one reaches the age of routine vaccination, the "wild" polioviruses and other enteroviruses that are so extensively disseminated in subtropical and tropical regions remain the dominant viruses in the community. This is another reason why the World Health Organization Expanded Immunization Programme, which is patterned after polio immunization programs of the temperate climate, developed countries will remain only partly effective in the undeveloped, tropical countries, even after the goal of routine vaccinations of a larger proportion of the children has been achieved.
In Poliomyelitis in the Tropics There is no question that more potent and very much more expensive IPV can be highly immunogenic and after multiple doses can produce very high titers of antibody that will persist for longer periods of time. However, as long as a large propor-tion of children receive either no vaccine at all or only one dose, IPV cannot be expected to accomplish more than OPV and, for a variety of other reasons, not as much. Melnick's recent recommendation [21] that multiple doses of IPV and OPV be used in routine vaccination as a means of eliminating paralytic poliomyelitis in the tropics is, in my judgment, based not only on an improper evaluation of the continuing greater incidence of paralytic disease among Arab children in Israel, the West Bank, and the Gaza strip than among Jewish children in Israel, but also on a disregard of the procedure by which OPV produces its maximum effect in such populations. He also failed to appreciate the impracticality of his proposal for impoverished populations with limited health services.
